
Acer Therapeutics ACER
Quartalsbericht 2023-Q3
hinzugefügt 20.11.2023
Acer Therapeutics Betriebsaufwand 2011-2026 | ACER
Betriebsaufwand Jährlich Acer Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.6 M | 17.2 M | 22.8 M | 29.9 M | 21.7 M | 13.9 M | 9.86 M | 14.6 M | 16.3 M | 13.2 M | 9.13 M | 5.97 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 29.9 M | 5.97 M | 16.6 M |
Betriebsaufwand Vierteljährlich Acer Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 4.29 M | 4.99 M | - | 5.24 M | 7.06 M | 7.05 M | - | 3.28 M | 3.63 M | 5.52 M | - | 5.89 M | 5.77 M | 4.97 M | - | 5.36 M | 11.2 M | 8.18 M | - | 4.11 M | 4.92 M | 3.99 M | - | 3.36 M | 3.01 M | 3.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 11.2 M | 3.01 M | 5.26 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 219.89 | 2.02 % | $ 5 B | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Omeros Corporation
OMER
|
174 M | $ 10.41 | 2.26 % | $ 606 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 19.54 | 1.61 % | $ 913 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Processa Pharmaceuticals
PCSA
|
6.44 M | $ 2.33 | - | $ 3.05 M | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.32 | - | $ 337 M | ||
|
Phathom Pharmaceuticals
PHAT
|
312 M | $ 10.41 | 3.48 % | $ 759 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
85.3 M | $ 8.29 | 1.28 % | $ 110 M | ||
|
CRISPR Therapeutics AG
CRSP
|
668 M | $ 47.2 | 1.66 % | $ 4.24 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
12 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | ||
|
Dynavax Technologies Corporation
DVAX
|
137 M | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
189 M | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Pliant Therapeutics
PLRX
|
156 M | $ 1.31 | 1.95 % | $ 80.4 M | ||
|
PMV Pharmaceuticals
PMVP
|
86.2 M | $ 1.38 | -1.08 % | $ 72.5 M | ||
|
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
52.2 M | $ 4.46 | 3.48 % | $ 855 M | ||
|
Homology Medicines
FIXX
|
36.8 M | - | 0.77 % | $ 53.4 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Prelude Therapeutics Incorporated
PRLD
|
117 M | $ 3.28 | 4.97 % | $ 252 M |